Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Garry Neil
AddedFeb 19, 2024
UpdatedMay 31, 2026
Garry Neil

Garry Neil

Board Member, Avalo Therapeutics

LinkedInThe Org

Garry Neil's Career

Avalo Therapeutics
Avalo Therapeutics

Rockville, MD, US

Board Member· Board
Celldex Therapeutics
Celldex Therapeutics

Hampton, NJ, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Garry Neil's Career

Avalo Therapeutics
Avalo Therapeutics
Public$46.5M422011Rockville, MD, US
Board Member· Board

Leadership at Avalo Therapeutics

Magnus PerssonMagnus PerssonBoard Member
Michael ColaMichael ColaBoard Member
Isaac BlechIsaac BlechCo-Founder
Solomon H SnyderSolomon H SnyderBoard Member
Gilla KaplanGilla KaplanBoard Member
Mitchell ChanMitchell ChanBoard Member

Similar to Avalo Therapeutics

Avalor TherapeuticsAvalor TherapeuticsKenmore, WA, USMedical TreatmentsAvalor TherapeuticsKenmore, WA, US

Kenmore-based medical organization, Avalor Therapeutics, pioneers precision medicine.

Pre-Seed · $335k6
Avalyn PharmaAvalyn PharmaSeattle, WA, USPharmaceuticalsest. 2011Avalyn PharmaSeattle, WA, US · est. 2011

Avalyn Pharma Inc.: Developing innovative therapies for Idiopathic Pulmonary Fibrosis.

Series C · $272.5M27
AvotresAvotresCedar Knolls, NJ, USCancer Therapy, Therapeuticsest. 2016AvotresCedar Knolls, NJ, US · est. 2016

Avotres: A biotech firm innovating therapies for immune diseases and potential cancer treatments.

Series A · $4M7
Ashvattha TherapeuticsAshvattha TherapeuticsRedwood City, CA, USBiopharmaceuticals, Therapeuticsest. 2015Ashvattha TherapeuticsRedwood City, CA, US · est. 2015

Ashvattha Therapeutics: Innovating biopharmaceuticals for human and veterinary use since 2016.

Series B · $98M42
Celldex Therapeutics
Celldex Therapeutics
Public$1.1B1481983Hampton, NJ, US
Board Member· Board

Leadership at Celldex Therapeutics

Harry H. PennerHarry H. PennerBoard Member
Anthony MarucciAnthony MarucciCo-Founder
James MarinoJames MarinoBoard Member
Herb ConradHerb ConradBoard Member
Tibor KelerTibor KelerCo-Founder
Karen L. ShoosKaren L. ShoosBoard Member

Similar to Celldex Therapeutics

ImmuneXciteImmuneXciteLexington, KY, USAntibodies, Therapeuticsest. 2007ImmuneXciteLexington, KY, US · est. 2007

US-based ImmuneXcite enhances therapeutic monoclonal antibodies' efficacy with its platform technology.

Series A · $15.7M10
Cellective BioTherapyCellective BioTherapyDurham, NC, USCancer Treatmentest. 2015Cellective BioTherapyDurham, NC, US · est. 2015

Cellective BioTherapy: Pioneering B cell-based therapies for personalized cancer treatment since 2015.

Angel · $2.5M7
MacroGenicsMacroGenicsRockville, MD, USest. 2000MacroGenicsRockville, MD, US · est. 2000

US-based MacroGenics, Inc. develops novel biologics for cancer, autoimmune disorders, and infectious diseases.

Public · $165.9M357
Ernexa TherapeuticsErnexa TherapeuticsCambridge, MA, USCell Therapiesest. 1984Ernexa TherapeuticsCambridge, MA, US · est. 1984

Eterna Therapeutics: Pioneering cell engineering for cancer and immunologic disease treatment.

Public · $49.1M11

People Similar to Garry Neil

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao